Image Source : Moneycontrol
Mankind Pharma reported stellar Q3FY26 results with consolidated revenue from operations at ₹35.67 billion and net profit at ₹4.09 billion. Driven by chronic therapies, OTC growth, and BSV integration, these figures highlight resilience amid market challenges, boosting investor confidence in India's pharma powerhouse.
Show more
Key Highlights
-
Revenue Surge: Consolidated revenue from operations reached ₹35.67 billion (₹3,567 crore), fueled by 20%+ domestic growth in chronic segments and robust exports.
-
Profit Strength: Net profit stood at ₹4.09 billion (₹409 crore), reflecting improved EBITDA margins from operational efficiencies and BSV consolidation.
-
Domestic Dominance: Base business outperformance in anti-infectives, modern trade; chronic portfolio share expanded, OTC up 30% YoY.
-
Strategic Wins: Exports soared 80%+, market share gains in top brands; R&D pipeline advances support long-term growth.
Forward View
With board approval on February 3, 2026, Mankind eyes sustained expansion via specialty drugs and digital health.
Sources: Univest.in, ScanX.Trade, CNBC TV18, Mankind Pharma Investor Relations.
Stay Ahead – Explore Now!
Steel Giant In Transition: Thyssenkrupp Explores Deal With Jindal Steel
Advertisement
Advertisement